Eli Lilly, Resilience to Invest $750 Million in Ohio Manufacturing Expansion

Eli Lilly and its contract manufacturing partner Resilience will invest $750 million to expand pharmaceutical production capacity in the United States, the companies announced Thursday. The joint investment aims to increase the supply of critical medicines amid soaring demand and will create 400 new high-skilled jobs in the Cincinnati, Ohio region.

Partnership Expansion

The investment will bolster Resilience’s manufacturing operations, which will now include the production of Eli Lilly’s KwikPen injectable device. This device is used for widely prescribed diabetes and obesity treatments, areas where Lilly has seen unprecedented growth and subsequent supply constraints.

This move deepens a multi-year manufacturing partnership that began in 2023. According to the announcement, the collaboration has already successfully produced more than 150 million doses of medicines for U.S. patients in vial and pre-filled syringe formats.

Scaling Up to Meet Demand

Ad

Edgardo Hernandez, Lilly’s head of manufacturing, stated that the partnership reflects the drugmaker's ongoing efforts to meet the significant increase in demand for its medicines. For investors, this signals a proactive strategy to address production bottlenecks for its blockbuster drugs, which is crucial for sustaining revenue growth.

This latest commitment is part of a much larger capital expenditure plan for the pharmaceutical giant. Since 2020, Eli Lilly has committed over $55 billion to expanding its manufacturing footprint in the U.S. and plans to break ground on several other new sites this year.

Industry Context

The move aligns with a broader trend among global drugmakers to increase U.S.-based manufacturing. This shift is partly driven by efforts to secure supply chains and potentially mitigate geopolitical risks, including potential tariffs on imported pharmaceuticals.